These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 28830541)

  • 1. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
    Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
    Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Hao W; Shi Y; Qin Y; Sun C; Chen L; Wu C; Bao Y; Liu S
    Integr Cancer Ther; 2020; 19():1534735420945017. PubMed ID: 32729334
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective effect of saffron total glycoside tablets in patients with breast cancer receiving anthracycline-based chemotherapy: study protocol for a multicentre, randomised, parallel, double-blind, placebo-controlled clinical trial.
    Su X; Li XY; Zhang YJ; Liu YS; Yuan C; Yang F; Liu C; Chen HW; Xiong XJ; Gao YH; Xing YW
    Ann Palliat Med; 2021 Jul; 10(7):8283-8291. PubMed ID: 34263648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
    Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
    Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.
    Nabati M; Janbabai G; Esmailian J; Yazdani J
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):233-241. PubMed ID: 30599756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
    Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
    BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
    Broeyer FJ; Osanto S; Suzuki J; de Jongh F; van Slooten H; Tanis BC; Bruning T; Bax JJ; Ritsema van Eck HJ; de Kam ML; Cohen AF; Mituzhima Y; Burggraaf J
    Br J Clin Pharmacol; 2014 Nov; 78(5):950-60. PubMed ID: 24844787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
    Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
    Cannata F; Stefanini G; Carlo-Stella C; Chiarito M; Figliozzi S; Novelli L; Lisi C; Bombace S; Panico C; Cosco F; Corrado F; Masci G; Mazza R; Ricci F; Monti L; Ferrante G; Santoro A; Francone M; da Costa BR; Jüni P; Condorelli G
    J Cardiovasc Med (Hagerstown); 2023 Jul; 24(7):469-474. PubMed ID: 37285278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
    [No Abstract]   [Full Text] [Related]  

  • 17. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
    Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    Kirkham AA; Paterson DI; Prado CM; Mackey JR; Courneya KS; Pituskin E; Thompson RB
    BMC Cancer; 2018 Sep; 18(1):864. PubMed ID: 30176834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
    Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
    J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.